Pages

Wednesday, March 25, 2015

FDA Approves New Treatment for Diabetic Retinopathy in Patients with Diabetic Macular Edema

... occlusions, both of which cause fluid to leak into the macula resulting in blurred vision. Eylea is marketed by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. Lucentis is marketed by South San Francisco, California-based Genentech, a ...

http://ift.tt/1EU6unS

No comments:

Post a Comment